OCCIDENT has been invested in Resistell since the seed financing and is now again participating in the first tranche of 8.5 million of the Series B.
Together with the EIC Fund, TRUMPF Venture, Zürcher Kantonalbank, Launchpad and other private investors, the foundation is thus laid for the next successful phase of the company.
Resistell is a leading MedTech company in the field of phenotypic nanomotion technology for measuring living cells through which antibiotic resistance can be tackled. The additional funding will be used to complete clinical trials for antibiotic susceptibility testing (AST) and to launch the R&D device Phenotech Research. This device shows in the first clinical study for bacteremia and sepsis an accuracy of about 95% and a massive reduction of time to result compared to the gold standard.
More information in the press release under the following Link.
More about Resistell
